Merit Medical Systems Inc Dossier - Source-backed chat

Merit Medical Systems Inc

MMSINASDAQ

SectorHealth Care

IndustryMedical Instruments & Supplies

Beta (adjusted)0.67

Intrinsic Value $98.94median of 6 methods · middle span $75-$134based on filings through 30 Jun 2026

Market Price $86.15Price as of 1 Oct 2026

Near fair valueIntrinsic value is 15% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $5.1B

Enterprise Value $5.4B

Shares Outstanding 59.5M diluted

Moat Rating Narrow

Next Earnings Date29 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Merit Medical Systems (MMSI) represents a compelling growth-and-margin-expansion story as it enters the final year of its Continued Growth Initiatives (CGI) Program. Under the leadership of new CEO Martha G. Aronson, the company is successfully transitioning its portfolio toward higher-margin therapeutic categories (such as oncology and endoscopy) while maintaining a stable foundational business. Despite near-term headwinds from tariffs and international market dynamics (particularly in China), Merit's strong execution is highlighted by its Q1 2026 earnings beat, raised full-year revenue guidance, and robust free cash flow generation. The strategic acquisition of View Point Medical for $140 million expands its addressable breast lesion localization market and is poised to become highly accretive to non-GAAP EPS and operating margins starting in FY 2027.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets11 analysts · as of 18 Aug 2026

Low · most bearish analyst$83.00

Mean target$100.27

High · most bullish analyst$114.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Integration delays with View Point Medical, combined with persistent volume-based procurement (VBP) pressures in China, drag down international sales. Tariff headwinds intensify, and organic growth slows to the low single digits, causing the company to miss the lower bound of its CGI operating margin target (20%). Valuation multiples compress further due to execution uncertainty under the new leadership.

Base CaseCentral scenario

The company successfully completes its CGI Program, achieving its multi-year targets of 5%-7% revenue CAGR, 20%-22% non-GAAP operating margins, and cumulative free cash flow exceeding $400 million. Organic constant currency growth stabilizes in the 4.5%-6.0% range, and the View Point Medical integration proceeds smoothly, contributing $2M-$4M in FY 2026 and ramping to $14M-$16M in FY 2027. Valuation multiples re-rate upward as macro headwinds (tariffs, China VBP) are effectively managed.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong Q1 2026 financial performance, beating consensus EPS estimates by 16% ($0.94 actual vs. $0.81 expected).
Strategic portfolio shift toward high-margin Therapeutic products (e.g., SCOUT, Resilience stent) which are growing at double-digit rates.
Highly disciplined M&A strategy, exemplified by the View Point Medical acquisition which expands the oncology addressable market and is accretive starting in FY 2027.
Robust balance sheet and cash flow profile, with $24.7 million in free cash flow generated in Q1 2026 (up 26% YoY) supporting self-funded growth.

Key Investment Risks

Geopolitical and macroeconomic headwinds, including ongoing tariff pressures representing a ~120-130 bps margin drag.
Geographic concentration risks and market softness in China due to volume-based procurement policies.
Execution and integration risks associated with the $140 million View Point Medical acquisition.
Leadership transition risks as the company executes its long-term strategy under CEO Martha G. Aronson following the departure of long-time founder Fred Lampropoulos.

Thesis Invalidation Triggers

Organic constant currency revenue growth falling below 3% for consecutive quarters.
Non-GAAP operating margins failing to reach the 20% threshold by the end of FY 2026.
A material downward revision in FY 2027 revenue expectations for the View Point Medical portfolio (below $14 million).
Severe regulatory or reimbursement setbacks for key therapeutic platforms such as WRAPSODY.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.